N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer

ConclusionTCHL was a tolerable regimen at a starting L dose of 750  mg PO daily when given concurrently with chemotherapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research